Sugi Predict

Sugi Predict / Compounds / SCHEMBL20003971

SCHEMBL20003971

SCHEMBL20003971

CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC1NC(=O)C2CCCN2C(=O)C(CCC(=O)O)NC(=O)C(Cc2ccccc2)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C2CCCN2C(=O)C(Cc2ccccc2)NC(=O)C(Cc2c[nH]cn2)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)CC(C)C)C(C)O)CSSCC(C(=O)NC(CCCCN)C(N)=O)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC1=O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 15/20 0.51
▸ MC4R P32245 2/20 0.50
▸ MC1R Q01726 2/20 0.50
▸ MC3R P41968 1/20 0.50
▸ GCGR P47871 2/20 0.49
▸ TEAD1 P28347 1/20 0.49
▸ NPY2R P49146 1/20 0.49
▸ KLK7 P49862 1/20 0.49
▸ CCKBR P32239 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20003972 0.98 MC4R (0.53) GLP1RMC4RMC1RMC3RGCGR
SCHEMBL20402542 0.98 MC4R (0.53) GLP1RMC4RMC1RMC3RGCGR
SCHEMBL23056722 0.98 TEAD1 (0.53) GLP1RMC4RMC1RMC3RGCGR
SCHEMBL27014090 0.98 TEAD1 (0.53) GLP1RMC4RMC1RMC3RGCGR
SCHEMBL23056750 0.97 GLP1R (0.51) GLP1RMC4RMC1RGCGRNPY2R
SCHEMBL20003981 0.96 MC4R (0.50) GLP1RMC4RMC1RMC3RGCGR
SCHEMBL26952437 0.91 MC4R (0.59) GLP1RMC4RMC1RMC3RGCGR
SCHEMBL20003753 0.89 PRLHR (0.58) GLP1RGCGRNPY2RCCKBR
SCHEMBL29393563 0.76 F11 (0.56) GLP1RMC4RMC1RMC3RGCGR
SCHEMBL24625820 0.75 KLK7 (0.53) KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016895-A1 HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE PROTAGONIST THERAPEUTICS, INC. 2024-01-18 — — US disclosed
WO-2023240077-A1 HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE PROTAGONIST THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
WO-2022266060-A1 HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS PROTAGONIST THERAPEUTICS, INC. (US) 2022-12-22 — — WO disclosed
WO-2021046246-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2021-03-11 — — WO disclosed
US-20210061872-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2021-03-04 — — US disclosed
US-10030061-B2 Hepcidin analogues and uses thereof PROTAGONIST THERAPEUTICS, INC. (US) 2018-07-24 — — US disclosed
US-20180086811-A1 HEPCIDIN ANALOGUES AND USES THEREOF PROTAGONIST THERAPEUTICS, INC. 2018-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030061-B2 Hepcidin analogues and uses thereof HAMP, SLC40A1, FTH1 GLP1R 294/4885MC4R 917/4885MC1R 281/4885
US-20240016895-A1 HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE HAMP, HBG1, HBG2 GLP1R 206/4885MC4R 1409/4885MC1R 487/4885
US-20180086811-A1 HEPCIDIN ANALOGUES AND USES THEREOF HAMP, SLC40A1, FTH1 GLP1R 298/4885MC4R 925/4885MC1R 282/4885
US-20210061872-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, HDGF, FTH1 GLP1R 120/4885MC4R 655/4885MC1R 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.